RE:RE:Almost a penny stock againYes Prothena Sad trial on
PRX012 Phase 1 SAD Phase 1 Trial Design: • Randomized, double-blind, placebo-controlled, SAD clinical trial • Up to 6 dose cohorts in healthy volunteer (HV) subjects and subjects with biologically confirmed Alzheimer’s disease • To assess safety and tolerability Healthy Volunteers (SubQ single dose) AD Patients (SubQ single dose) Primary Objective: • To evaluate the safety and tolerability of PRX012 when administered as a single dose Secondary Objectives: • To characterize the plasma PK profile of PRX012 and cerebrospinal fluid PK profile of PRX012 after subcutaneous administration as a single dose Randomize 3:1 N = ~ 50 total subjects and patients